Navigation Links
Merz research Shows Long-term Benefits for Patients With Dystonia

FRANKFURT AM MAIN, Germany, October 21, 2011 /PRNewswire/ --

At the 5th International Dystonia Symposium (IDS) in Barcelona, Spain (20-22 October 2011), Merz Pharmaceuticals presented important clinical data concerning the long-term, sustained efficacy and safety of XEOMIN® for the treatment of patients with dystonia.

Dystonia is a particularly debilitating condition where involuntary muscle contractions can cause abnormal twisting, postures or movements, and is the third most common movement disorder after essential tremor and Parkinson's disease.[1] New data presented at recent neurological congresses and summarized at the IDS indicate that patients treated with XEOMIN® for cervical dystonia or blepharospasm (involuntary closing of the eyelids) experienced long-term sustained efficacy with a favorable safety profile in studies of up to 121 and 88 weeks duration, respectively.[2-4] Furthermore, the incidence of adverse events decreased with each injection session, indicating no cumulative effect of the drug with repeated treatments.[2,4] Professor Alberto Albanese from the Istituto Neurologico Carlo Besta, Milan, Italy, who is the lead author of the recently published new European Federation of Neurological Societies guidelines on the diagnosis and treatment of dystonia,[5] stated that "Botulinum neurotoxin type A should be regarded as the first-line treatment for patients with dystonia. It is also important to know that repeated treatments are safe and efficacious over many years. These data give physicians more confidence in using this medication over the long term".

Professor Alberto Albanese indicated that "most patients with dystonia require long-term treatment. Moreover flexibility is needed with respect to time interval between treatment sessions to facilitate individualized care. Long-term clinical studies involving XEOMIN® are unique in being able to show that patients can be dosed safely also with injection intervals ranging from 6 to 20 weeks".[6] Individualized patient treatment also requires the use of different doses depending on the severity of dystonia and the muscle affected. XEOMIN® is now available in both 100 and 50 unit vials,[7,8] which limits product wastage and may result in significant cost savings for healthcare providers.

Comparative clinical study results suggest that XEOMIN® and the comparator product containing conventional Botulinum toxin type A complex (900 kD) are of equal potency when used with a dosing conversion ratio of 1:1.[7,9,10] In addition, XEOMIN® is the only product in its class to be refined by an FDA-approved state-of-the-art biotechnology process to remove the unnecessary accessory or complexing proteins that would otherwise be injected into the patient along with the active 150 kD neurotoxin.[7,8,11,12]


Botulinum toxin type A is naturally produced by Clostridium botulinum as a larger protein complex containing therapeutically unnecessary accessory or complexing proteins. XEOMIN® (incobotulinumtoxinA) is manufactured using an FDA-approved state-of-the-art biotechnological process, which draws out the pure neurotoxin with a low foreign protein content. Foreign proteins are considered as one of the factors for secondary therapy failure.[7]

Since its launch in 2005, more than 261,000 patients have been treated with XEOMIN® worldwide.[13] It is approved in 21 countries for the treatment of blepharospasm, cervical dystonia (spasmodic torticollis), and in 17 countries for post-stroke spasticity of the upper limb (XEOMIN® is not approved for the treatment of spasticity in the US). Due to unit differences in the LD50 assay, XEOMIN units are specific to XEOMIN®. Therefore unit doses recommended for XEOMIN® are not interchangeable with those for other preparations of Botulinum toxin. Comparative clinical study results suggest that XEOMIN® and the comparator product containing conventional Botulinum toxin type A complex (900 kD) are of equal potency when used with a dosing conversion ratio of 1:1.[7]

XEOMIN® is the only botulinum toxin product that does not require refrigeration during transport or storage.

XEOMIN® is now available in 50 and 100 unit vials. The new 50 unit vial helps facilitate flexible dosing and offers reduced product wastage as well as cost savings.

About Merz Pharmaceuticals GmbH (

Merz Pharmaceuticals, a member of the Merz Pharma Group of companies, is an innovative and international specialty healthcare company specializing in the research, development and marketing of pharmaceuticals for the treatment of neurological and psychiatric diseases. In addition to developing XEOMIN®, the company has developed memantine (Namenda®, Memary®,Axura®, Ebixa®) - the first drug for the treatment of moderate to severe Alzheimer's disease, which is marketed by Forest in the US, Daiichi Sankyo in Japan, and Merz/Lundbeck in Europe and rest of the world. The company also focuses on the development of innovative therapies within the therapeutic areas of hepatology, metabolic diseases and dermatology.


  1. Defazio G. Eur J Neurol. 2010 Jul;17 Suppl 1:9-14.
  2. Grafe S, Hanschmann A. Poster presented at AAN 2010. Neurol J 2010; 74 (Suppl 2): A88.
  3. Dressler D et al. Poster presented at EFNS 2011;
  4. Grafe S et al. Poster presented at MDS 2010. Mov Disord 2010; 25 (Suppl 2): S235.
  5. Albanese A et al. Eur J Neurol 2011; 18: 5-18.
  6. Truong et al. Poster presented at MDS 2011. Mov Disord 2011; 26 (Suppl 2): S211.
  7. XEOMIN® 50 U Summary of Product Characteristics. May 2011, UK.
  8. XEOMIN® US Prescribing Information. July 2011, US.
  9. Benecke R et al. Neurology 2005; 64: 1949-1951.
  10. Roggenkämper P et al. J Neural Transm 2006; 113: 303-312.
  11. Bigalke H. In: Jankovic J et al. Botulinum toxin - therapeutic clinical practice and science. Philadelphia, PA: Saunders Elsevier; 2009.
  12. Frevert J. Drugs R D 2010; 10: 67-73.
  13. Merz, data on file, 2010, XEO-DOF-2010-11-001.

XEOMIN® is a registered trademark of Merz Pharma GmbH & Co KGaA.  

For information:
Ute Weinhold
Merz GmbH & Co. KGaA
Eckenheimer Landstraße 100
60318 Frankfurt
Tel: +49-69-15-03-889 


SOURCE Merz Pharmaceuticals GmbH
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Critical Alerts For Intel, Mosaic, Deckers, Foot Locker, and Jazz Pharmaceuticals Released By Seven Summits Research
2. Bend Research Announces New Chief Financial Officer
3. SANYO Offers Researchers Energy-Efficient, Space-Saving Solutions for Biological Sample Preservation
4. Clinical Research Sites Honor Top Sponsor, CRO and IRB at 2011 Site Solutions Summit
5. VaxyGen Manufacturing Services LLC Announces Exclusive License and Collaborative Agreement with Georgia State University Research Foundation to Commercialize Novel Biological Process Development Patent, Expertise & Know-How
6. SomaLogic Announces Research Agreement with Leading Global Pharmaceutical Company to Accelerate Pharmaceutical Discovery and Development
7. Rock Creek Pharmaceuticals Announces Expanded International Shipping Options for Anatabloc™, Physician Conferences on Anatabine Research
8. Aethlon Medical Announces Availability of its Exosome Detection Assay to the Research Community
9. Bend Research Announces Schedule of Events at 2011 AAPS Annual Meeting and Exposition
10. VisionSpring Research Finds Seeing to be the Most Important of Five Senses
11. Techstreet and the ISPE Extend Partnership to Expedite Drug Research with Subscription Offering for Life Science Engineers
Post Your Comments:
(Date:10/13/2015)... 2015  Kay Elledge, M.D., an established South ... of Obstetrics and Gynecology (FACOG) for the past ... Genuine Self Medical Laser Center where she provides ... of Breast Cancer Awareness Month , the ... MonaLisa Touch treatments initiated in the month ...
(Date:10/13/2015)... 13, 2015  Human Longevity, Inc. (HLI), the genomics-based, ... announced today the launch of the company,s first Health ... the potential to transform healthcare. The inaugural Health Nucleus ... , at HLI,s headquarters facility. More Health Nucleus facilities ... and International cities. --> ...
(Date:10/13/2015)... SAN DIEGO , Oct. 13, 2015 /PRNewswire/ ... bioelectronics for use in research and diagnostics, announces ... of $1.6 million led by Serra Ventures. ... Nanomed,s mission is providing low-cost, easy-to-use monitoring and ... personal health decisions. The funding round will enable ...
Breaking Medicine Technology:
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... solution provider of IBM software products, introduced a new company, RightSensor™ LLC, an ... and data communications capability. RightSensor™ provides a fully-managed approach for customers requiring ...
(Date:10/13/2015)... ... 13, 2015 , ... Dr. Poneh Ghasri, dentist in West Hollywood , ... The research, which was conducted at the Dental Institute at King's College London in ... stress during pregnancy and future dental health in the child. For years, researchers have ...
(Date:10/13/2015)... ... October 13, 2015 , ... A child without a healthy mouth is ... the leading remote invisible aligner system, has joined with Global Dental Relief ... For each aligner treatment plan purchased, SmileCareClub will donate one clinic visit to a ...
(Date:10/13/2015)... Hills, CA (PRWEB) , ... October 13, 2015 ... ... management and workflow solutions, announced today their Title Sponsorship of Synergy 2015. The ... in Henderson, NV at Green Valley Ranch and will unite customers, partners, WennSoft ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... Illinois with more than 59,000 emergency department visits per year, today announced the ... T-System, to help improve clinical, operational and financial outcomes. , In ...
Breaking Medicine News(10 mins):